Mitesh Borad, MD
Hematology & Oncology · Scottsdale, AZNPI 1801850573
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,266 of the $50,992 with a category attached, or 79.0%. 21 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 24.2% of the total. Reporting peaked in 2023 at $21,819 and has fallen 97.7% since, to $511 in 2025.
Across 62 payments — averaging $822.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$12K
- Merck$10K
- Modernatx, Inc.$5K
- AstraZeneca$4K
- Genentech USA, Inc.$4K
- Boehringer Ingelheim$4K
- plus $12K from 15 others
Across 564 payments — averaging $6255.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$862K
- Incyte Corporation$744K
- Astellas Pharma Global Development$359K
- EMD Serono, Inc.$297K
- Agios Pharmaceuticals, Inc.$270K
- Pfizer$178K
- plus $818K from 16 others
What the payments were for
- Consulting fees$40,26679%
- Speaking & faculty fees$3,9518%
- Travel & lodging$3,4677%
- Food & beverage$3,2966%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 10 | $12,315 |
| Merck | 11 | $9,884 |
| Modernatx, Inc. | 2 | $4,898 |
| AstraZeneca | 5 | $4,394 |
| Genentech USA, Inc. | 7 | $3,946 |
| Boehringer Ingelheim | 1 | $3,900 |
| LES Laboratoires Servier | 1 | $3,156 |
| Eisai Inc. | 5 | $2,791 |
| Exelixis Inc. | 1 | $1,980 |
| Servier Pharmaceuticals LLC | 2 | $1,971 |
| Tersera Therapeutics LLC | 4 | $352 |
| Ipsen Biopharmaceuticals, Inc | 2 | $258 |
| Tempus AI, Inc | 2 | $209 |
| Astrazeneca AB | 2 | $188 |
| Redhill Biopharma Inc. | 1 | $178 |
| Novartis | 1 | $177 |
| AVEO Pharmaceuticals, Inc. | 1 | $161 |
| Coherus Oncology, Inc. | 1 | $121 |
| Lexicon Pharmaceuticals, Inc. | 1 | $87 |
| Taiho Oncology, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,992 in reported general payments places this provider in the 85th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 26 | $316 |
| Dexamethasone | 18 | $181 |
| Ondansetron Hcl | 22 | $168 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Scottsdale
- Jeffrey SchriberScottsdale$715K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Yousef ZakhariaScottsdale$214K
- Thai HoScottsdale$190K
- Alan BryceScottsdale$157K
- Daniel AhnScottsdale$91K
- Brendan CurleyScottsdale$87K
- Alexander StewartScottsdale$76K
- Saurabh ChhabraScottsdale$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.